Guggenheim lowered the firm’s price target on Olema Oncology (OLMA) to $38 from $40 and keeps a Buy rating on the shares. Olema reiterated timelines for the Phase 3 palazestrant monotherapy readout in fall 2026 and first Phase 1 KAT6 data at a medical meeting in Q2, but external details of Roche’s (RHHBY) persevERA study and the results of AstraZeneca’s (AZN) SERENA-4 trial will shape the investor view of the first-line oral SERD opportunity, the analyst says.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Oncology price target raised to $62 from $60 at Citi
- Olema Pharmaceuticals: Palazestrant Phase III Upside and Differentiated Pipeline Underpin Buy Rating
- Buy Rating Reaffirmed on Palazestrant’s Differentiated Phase 3 Program and Favorable Risk‑Reward Profile for Olema
- Olema Oncology reports Q4 EPS (50c), consensus (53c)
- Maintaining a Buy on Olema: Differentiated Palazestrant Profile Supports Upside Despite Negative Giredestrant Read-Through